Drugs online research references
Pharmacology. 2000 Jan;60(1):51-6.
Simultaneous determination of paroxetine, risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography with coulometric detection.
Schatz DS, Saria A.
Division of Neurochemistry, Department of Psychiatry, University Hospital Innsbruck, Austria.
A method for the simultaneous determination of paroxetine, risperidone and its main metabolite 9-hydroxyrisperidone in human plasma has been developed. The procedure involved a multistep solid-phase liquid extraction with an internal standard. The drugs were separated on a cyano column followed by coulometric detection. This method described here has sufficient sensitivity to quantitate paroxetine accurately in the range 5-500 ng/ml with a lower limit of detection of 1 ng/ml and risperidone and its main metabolite 9-hydroxyrisperidone in the range 2-100 ng/ml with a lower limit of detection of 1 ng/ml when 1 ml of plasma was used for the analysis. The precision, accuracy and specificity have been proven, and show that the method is reliable for clinical studies and routine drug monitoring. Copyright 2000 S. Karger AG, Basel
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10629444&dopt=Abstract
note: kwd match paxil online literature
Neuropsychobiology. 1996;34(4):184-7.
Decreased platelet 3H-paroxetine binding in obsessive-compulsive patients.
Marazziti D, Rossi A, Gemignani A, Giannaccini G, Pfanner C, Milanfranchi A, Presta S, Lucacchini A, Cassano GB.
Istituto di Psichiatria, Universita di Pisa, Italia.
The similarities between the serotonin (5-HT) transporter in both human platelets and human brain permit us to investigate this structure in patients with different psychiatric disorders. Several reports have shown abnormalities of the 5-HT transporter, by means of the measurement of the 5-HT uptake or of the 3H-imipramine binding, in platelets of patients with obsessive-compulsive disorder (OCD). The availability of the ligand 3H-paroxetine, a selective 5-HT reuptake inhibitor, to label the 5-HT transporter, promoted us to evaluate the binding of 3H-paroxetine in platelets of 18 drug-free patients with OCD. The results, showing that the patients had a lower number of 3H-paroxetine sites, which is inversely correlated with the Yale Brown Obsessive-Compulsive Scale total score, than a similar group of controls, add supporting evidence to the involvement of 5-HT in OCD. In addition, the decreased functionality of the 5-HT transporter seems to be linked to the severity of OC symptoms.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9121618&dopt=Abstract
note: kwd match paxil online literature
Clin Pharmacol Ther. 1997 Apr;61(4):476-87.
Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.
Modell JG, Katholi CR, Modell JD, DePalma RL.
Department of Psychiatry, University of Alabama at Birmingham School of Medicine 35294-0018, USA.
OBJECTIVE: To investigate patient reported prosexual side effects of the aminoketone antidepressant bupropion (INN, amfebutamone) and to compare directly the sexual side effects of bupropion and the selective serotonin reuptake inhibitor (SSRI) antidepressants fluoxetine, paroxetine, and sertraline. METHODS: One hundred seven psychiatric outpatient respondents receiving current treatment with one of the above antidepressants anonymously completed questionnaires that allowed reporting of both decreases and increases in sexual function. The main outcome measures were antidepressant-associated changes in libido, arousal, duration of time from arousal to orgasm, intensity of orgasm, and duration of orgasm relative to that experienced before the onset of the patients' psychiatric illnesses. RESULTS: Bupropion-treated patients reported significant increases in libido, level of arousal, intensity of orgasm, and duration of orgasm beyond levels experienced premorbidly. The three SSRIs to an equal degree significantly decreased libido, arousal, duration of orgasm, and intensity of orgasm below levels experienced premorbidly. Overall, 27% of the SSRI-treated patients had no adverse sexual side effects; in contrast, 86% of patients treated with bupropion had no adverse sexual effects, and 77% of bupropion-treated patients reported at least one aspect of heightened sexual functioning. CONCLUSIONS: SSRI-induced adverse sexual effects appear to be the rule rather than the exception and may be substantially underreported unless patients are specifically asked about the effects of these medications on various aspects of sexual function. In contrast, prosexual effects were reported by the majority of patients treated with bupropion. The findings are reviewed in light of the neurochemistry of these agents and the sexual response.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9129565&dopt=Abstract
note: kwd match paxil online literature
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Antibiotics and prescription medications online literature ||